Viking Therapeutics, Inc. Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

VKTX

Classificação em ações #4532
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Preço da ação
$26.38
Última sincronização: 2026-10-21
Valor de mercado
$3.35B
Variação (1 dia)
-1.23%
Variação (1 ano)
-16.04%
País
US
Negociar Viking Therapeutics, Inc. (VKTX)

Categoria

Healthcare
Histórico de preços das ações de Viking Therapeutics, Inc. (VKTX)
Preço de fecho mais alto: $27.60 em 2026-10-01

Preço de fecho mais baixo: $8.59 em 2015-04-01
Histórico de preços das ações da Viking Therapeutics, Inc. de 2015 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) -7.84%
2025 -20.83%
2024 152.59%
2023 215.71%
2022 16.84%
2021 -21.08%
2020 -20.48%
2019 -10.51%
2018 130.53%
2017 246.93%
2016 -60.36%
2015 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$527.18 23.62%
US
$251.29 835.90%
US
$137.83 -3.78%
AU
$890.85 9.42%
NL
$752.87 7.01%
CH